Jones Day Reps Sanofi In $560M TargeGen Buy

Law360, New York (June 30, 2010, 2:22 PM EDT) -- Sanofi-Aventis SA said Wednesday that it would pay up to $560 million to buy biotechnology company TargeGen Inc. and commercialize one of its treatments for blood disorders.

The French pharmaceutical giant said it would make a $75 million up-front payment for rights to TargeGen's most advanced drug candidate, followed by milestone payments if the company meets certain goals, for a total of up to $560 million for the acquisition.

The deal is a further step to increase Sanofi's presence in the field of hematological malignancies, according...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.